Publications

2021

Adib E, Nassar AH, Akl EW, Alaiwi SA, Nuzzo PV, Mouhieddine TH, et al. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021;27(14):4025-4035.
Pappa T, Ahmadi S, Marqusee E, Johnson HL, Nehs MA, Cho NL, et al. Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E -Driven Papillary Thyroid Cancer Patients. Clin Cancer Res. 2021;27(15):4256-4264.
Fine SW, Trpkov K, Amin MB, Algaba F, Aron M, Baydar DE, et al. Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urol Oncol. 2021;39(5):295.e1-295.e8.
Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, et al. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. J Clin Invest. 2021;131(10).
Xie X, Yu J, Qi Z, Bao L, Shen Y, Chen T, et al. [Experience and lessons on guiding and governing clinical applications of chromosome microarray analysis in the United States]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2021;38(5):419-424.
Pernar CH, Parmigiani G, Giovannucci EL, Rimm EB, Tyekucheva S, Loda M, et al. Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2021;30(4):751-756.
Mueller AC, Piper M, Goodspeed A, Bhuvane S, Williams JS, Bhatia S, et al. Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer. Cancer Res. 2021;81(12):3255-3269.
Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, et al. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature. 2021;589(7841):299-305.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700